ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN?S DISEASE: results of a Latin American single-center observational study

Context Adalimumab is a fully-human antibody that inhibits TNF alpha, with a significant efficacy for long-term maintenance of remission. Studies with this agent in Latin American Crohn’s disease patients are scarce. Objectives The objective of this study was to outline clinical remission rates af...

Full description

Bibliographic Details

Published in:	Arquivos de Gastroenterologia
Main Authors:	Paulo Gustavo KOTZE, Vinícius Rezende ABOU-REJAILE, Luciana Aparecida UIEMA, Marcia OLANDOSKI, Maria Cristina SARTOR, Eron Fábio MIRANDA, Lorete Maria da Silva KOTZE, Rogério SAAD-HOSSNE
Format:	Article
Language:	English
Published:	Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE) 2014-03-01
Subjects:	Fator de necrose tumoral alfa Antagonistas adrenérgicos alfa, administração e dosagem Doença de Crohn, prevenção e controle
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032014000100039&lng=en&tlng=en